NasdaqGS - Nasdaq Real Time Price USD

Novavax, Inc. (NVAX)

Compare
8.85
+0.28
+(3.27%)
At close: January 3 at 4:00:01 PM EST
8.82
-0.03
(-0.34%)
After hours: 7:52:18 PM EST
Loading Chart for NVAX
DELL
  • Previous Close 8.57
  • Open 8.57
  • Bid 8.81 x 700
  • Ask 8.85 x 200
  • Day's Range 8.52 - 8.86
  • 52 Week Range 3.53 - 23.86
  • Volume 2,939,253
  • Avg. Volume 5,068,614
  • Market Cap (intraday) 1.418B
  • Beta (5Y Monthly) 2.09
  • PE Ratio (TTM) --
  • EPS (TTM) -2.25
  • Earnings Date Feb 26, 2025 - Mar 3, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 16.00

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

www.novavax.com

1,543

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NVAX

View More

Performance Overview: NVAX

Trailing total returns as of 1/3/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

NVAX
11.60%
S&P 500
0.60%

1-Year Return

NVAX
75.94%
S&P 500
25.29%

3-Year Return

NVAX
93.81%
S&P 500
24.68%

5-Year Return

NVAX
97.10%
S&P 500
82.40%

Compare To: NVAX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NVAX

View More

Valuation Measures

As of 1/2/2025
  • Market Cap

    1.37B

  • Enterprise Value

    696.56M

  • Trailing P/E

    --

  • Forward P/E

    8.08

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.45

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    0.82

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -32.18%

  • Return on Assets (ttm)

    -10.76%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    885.19M

  • Net Income Avi to Common (ttm)

    -284.86M

  • Diluted EPS (ttm)

    -2.25

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    909.53M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -247.39M

Research Analysis: NVAX

View More

People Also Watch